4//SEC Filing
FLESHNER NEIL E. 4
Accession 0001104659-21-087826
CIK 0001811764other
Filed
Jun 29, 8:00 PM ET
Accepted
Jun 30, 9:27 PM ET
Size
8.9 KB
Accession
0001104659-21-087826
Insider Transaction Report
Form 4
FLESHNER NEIL E.
DirectorChief Medical Officer
Transactions
- Award
Common Stock
2021-06-30+3,587,249→ 3,587,249 total - Award
Common Stock
2021-06-30+233,171→ 233,171 total(indirect: 1510789 Ontario Inc.) - Award
Common Stock
2021-06-30+358→ 358 total(indirect: By Trust)
Footnotes (3)
- [F1]On June 30, 2021, POINT BIOPHARMA GLOBAL INC. (f/k/a Therapeutics Acquisition Corp., the "Issuer") consummated a business combination (the "Business Combination") pursuant to which RACA, Bodhi Merger Sub, Inc., a wholly-owned subsidiary of the Issuer merged with and into POINT Biopharma Inc., ("Old POINT"). At the effective time of the Business Combination, each share of Old POINT outstanding as of immediately prior to the effective time was exchanged for shares of Common Stock of the Issuer based on an implied Old POINT vested equity value of $585,000,000. As a result, the Reporting Person received the reported shares of the Issuer's Common Stock in consideration for the equity securities of Old POINT held by the Reporting Person prior to the Business Combination.
- [F2]A corporation controlled by Reporting Person
- [F3]A trust, whose trustee is the Reporting Person's spouse.
Documents
Issuer
POINT Biopharma Global Inc.
CIK 0001811764
Entity typeother
Related Parties
1- filerCIK 0001868209
Filing Metadata
- Form type
- 4
- Filed
- Jun 29, 8:00 PM ET
- Accepted
- Jun 30, 9:27 PM ET
- Size
- 8.9 KB